TABLE 3. Receipt of HIV medical care and viral suppression among Hispanics or Latinos aged ≥13 years with HIV infection diagnosed by December 31, 2013,* who were alive on December 31, 2014, by age group and selected characteristics — National HIV Surveillance System, 38 jurisdictions,† United States, 2015.
| Characteristic | Total no. | Receipt of HIV care in 2014 |
Viral suppression** |
|
|---|---|---|---|---|
| Any care§ |
Retained in care¶ |
|||
| No. (%) | No. (%) | No. (%) | ||
|
Age ≥13 yrs††
| ||||
|
Sex
| ||||
| Male |
113,284 |
78,214 (69.0) |
64,661 (57.1) |
65,532 (57.8) |
| Female |
28,645 |
21,375 (74.6) |
18,048 (63.0) |
17,108 (59.7) |
|
Transmission category§§
| ||||
| Male-to-male sexual contact |
79,146 |
56,407 (71.3) |
46,256 (58.4) |
48,027 (60.7) |
|
Injection drug use
| ||||
| Male |
15,733 |
9,026 (57.4) |
7,770 (49.4) |
7,318 (46.5) |
| Female |
7,244 |
5,269 (72.7) |
4,510 (62.3) |
4,064 (56.1) |
| Male-to-male sexual contact and injection drug use |
8,086 |
5,982 (74.0) |
4,981 (61.6) |
4,636 (57.3) |
|
Heterosexual contact¶¶
| ||||
| Male |
9,143 |
5,967 (65.3) |
4,983 (54.5) |
4,974 (54.4) |
| Female |
20,303 |
15,259 (75.2) |
12,831 (63.2) |
12,495 (61.5) |
| Other*** |
2,274 |
1,678 (77.1) |
1,378 (60.6) |
1,126 (49.5) |
|
Total
|
141,929
|
99,589 (70.2)
|
82,709 (58.3)
|
82,640 (58.2)
|
|
Age 13–24 yrs††
| ||||
|
Sex
| ||||
| Male |
4,493 |
3,466 (77.1) |
2,689 (59.8) |
2,530 (56.3) |
| Female |
1,298 |
1,000 (77) |
817 (62.9) |
631 (48.6) |
|
Transmission category§§
| ||||
| Male-to-male sexual contact |
3,558 |
2,767 (77.8) |
2,116 (59.5) |
2,081 (58.5) |
|
Injection drug use
| ||||
| Male |
51 |
40 (77.1) |
31 (61.1) |
25 (48.8) |
| Female |
64 |
45 (70.4) |
37 (58.4) |
30 (46.5) |
| Male-to-male sexual contact and injection drug use |
162 |
123 (75.8) |
96 (59.1) |
71 (43.5) |
|
Heterosexual contact¶¶
| ||||
| Male |
78 |
55 (70.9) |
47 (60.4) |
42 (53.8) |
| Female |
514 |
388 (75.6) |
310 (60.4) |
257 (50.0) |
| Other*** |
1,365 |
1,048 (76.8) |
869 (63.3) |
656 (48.1) |
|
Subtotal
|
5,791
|
4,466 (77.1)
|
3,506 (60.5)
|
3,161 (54.6)
|
|
Age 25–34 yrs††
| ||||
|
Sex
| ||||
| Male |
19,983 |
14,229 (71.2) |
11,138 (55.7) |
11,191 (56.0) |
| Female |
3,855 |
2,752 (71.4) |
2,172 (56.3) |
2,007 (52.1) |
|
Transmission category§§
| ||||
| Male-to-male sexual contact |
16,715 |
12,054 (72.1) |
9,416 (56.3) |
9,637 (57.7) |
|
Injection drug use
| ||||
| Male |
713 |
398 (55.7) |
320 (44.8) |
278 (38.9) |
| Female |
538 |
388 (72.0) |
295 (54.8) |
251 (46.6) |
| Male-to-male sexual contact and injection drug use |
1,201 |
917 (76.3) |
735 (61.2) |
626 (52.1) |
|
Heterosexual contact¶¶
| ||||
| Male |
1,052 |
660 (62.7) |
512 (48.7) |
517 (49.1) |
| Female |
3,077 |
2,179 (70.8) |
1,723 (56.0) |
1,631 (53.0) |
| Other*** |
542 |
386 (77.1) |
309 (57.0) |
259 (47.8) |
|
Subtotal
|
23,838
|
16,981 (71.2)
|
13,310 (55.8)
|
13,198 (55.4)
|
|
Age 35–44 yrs††
| ||||
|
Sex
| ||||
| Male |
29,744 |
20,299 (68) |
16,476 (55.4) |
16,921 (56.9) |
| Female |
7,253 |
5,343 (74) |
4,341 (59.9) |
4,131 (57.0) |
|
Transmission category§§
| ||||
| Male-to-male sexual contact |
22,581 |
15,780 (70) |
12,846 (56.9) |
13,419 (59.4) |
|
Injection drug use
| ||||
| Male |
2,468 |
1,399 (57) |
1,131 (45.8) |
1,063 (43.1) |
| Female |
1,521 |
1,108 (73) |
883 (58.1) |
787 (51.7) |
| Male-to-male sexual contact and injection drug use |
2,145 |
1,551 (72) |
1,236 (57.7) |
1,185 (55.2) |
|
Heterosexual contact¶¶
| ||||
| Male |
2,482 |
1,518 (61) |
1,225 (49.4) |
1,212 (48.8) |
| Female |
5,714 |
4,222 (74) |
3,446 (60.3) |
3,333 (58.3) |
| Other*** |
86 |
65 (77.8) |
50 (58.1) |
53 (61.6) |
|
Subtotal
|
36,997
|
25,642 (69.3)
|
20,817 (56.3)
|
21,052 (56.9)
|
|
Age 45–54 yrs††
| ||||
|
Sex
| ||||
| Male |
37,491 |
26,015 (69.4) |
21,894 (58.4) |
22,281 (59.4) |
| Female |
9,436 |
7,192 (76.2) |
6,201 (65.7) |
5,882 (62.3) |
|
Transmission category§§
| ||||
| Male-to-male sexual contact |
24,927 |
17,898 (71.8) |
15,008 (60.2) |
15,703 (63.0) |
|
Injection drug use
| ||||
| Male |
6,253 |
3,696 (59.1) |
3,165 (50.6) |
2,959 (47.3) |
| Female |
3,008 |
2,237 (74.4) |
1,961 (65.2) |
1,740 (57.9) |
| Male-to-male sexual contact and injection drug use |
3,094 |
2,294 (74.2) |
1,947 (62.9) |
1,834 (59.3) |
|
Heterosexual contact¶¶
| ||||
| Male |
3,146 |
2,080 (66.1) |
1,737 (55.2) |
1,741 (55.4) |
| Female |
6,384 |
4,924 (77.1) |
4,213 (66.0) |
4,115 (64.5) |
| Other*** |
115 |
78 (70.5) |
63 (54.8) |
68 (59.1) |
|
Subtotal
|
46,927
|
33,207 (70.8)
|
28,095 (59.9)
|
28,163 (60.0)
|
|
Age ≥55 yrs††
| ||||
|
Sex
| ||||
| Male |
21,573 |
14,205 (65.8) |
12,464 (57.8) |
12,609 (58.4) |
| Female |
6,803 |
5,088 (74.8) |
4,517 (66.4) |
4,457 (65.5) |
|
Transmission category§§
| ||||
| Male-to-male sexual contact |
11,364 |
7,908 (69.6) |
6,870 (60.5) |
7,186 (63.2) |
|
Injection drug use
| ||||
| Male |
6,248 |
3,495 (55.9) |
3,123 (50.0) |
2,993 (47.9) |
| Female |
2,113 |
1,492 (70.6) |
1,334 (63.1) |
1,256 (59.4) |
| Male-to-male sexual contact and injection drug use |
1,485 |
1,098 (73.9) |
967 (65.1) |
921 (62.0) |
|
Heterosexual contact¶¶
| ||||
| Male |
2,385 |
1,653 (69.3) |
1,461 (61.3) |
1,462 (61.3) |
| Female |
4,615 |
3,546 (76.8) |
3,139 (68.0) |
3,159 (68.4) |
| Other*** |
166 |
102 (68.0) |
88 (53.0) |
90 (54.2) |
| Subtotal | 28,376 | 19,293 (68.0) | 16,981 (59.8) | 17,066 (60.1) |
Abbreviation: HIV = human immunodeficiency virus.
* Data are based on address of residence as of December 31, 2014 (i.e., most recent known address). Hispanics or Latinos might be of any race.
† The 38 jurisdictions were Alabama, Alaska, California, Colorado, Connecticut, Delaware, the District of Columbia, Georgia, Hawaii, Illinois, Indiana, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Mexico, New York, North Dakota, Oregon, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.
§ Defined as having at least one CD4 or VL test performed during 2014, among persons diagnosed through December 31, 2013, and alive on December 31, 2014.
¶ Defined as having two or more CD4 or VL tests performed ≥3 months apart during 2014, among persons diagnosed through December 31, 2013, and alive on December 31, 2014.
** Defined as having a VL result of ≤200 copies/mL at the most recent VL test during 2014. The cut-off value of ≤200 copies/mL was based on the U.S. Department of Health and Human Services recommended definition of virologic failure. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/15/virologic-failure.
†† Age at year-end 2014.
§§ Data statistically adjusted using multiple imputation techniques to account for missing transmission categories.
¶¶ Heterosexual contact with a person known to have or to be at high risk for HIV infection.
*** Includes persons with diagnosed infection attributed to hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.